SCHEMBL4091037

SCHEMBL4091037

CCOC(=O)c1c(NC(=O)C2CC3CCC2(OC)CC3)sc2c1CCOC2

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
ALDH1A1 P00352 4/20 0.50
LMNA P02545 2/20 0.50
KMT2A Q03164 1/20 0.49
CNR2 P34972 9/20 0.47
CNR1 P21554 2/20 0.47
HTT P42858 1/20 0.45
TSHR P16473 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 3/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HPGD P15428 1/20 0.42
BLM P54132 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090835 0.81 KMT2A (0.55) MAPTALDH1A1LMNAKMT2ACNR2
SCHEMBL5450569 0.81 KMT2A (0.69) MAPTALDH1A1LMNAKMT2ACNR2
SCHEMBL4080930 0.80 CNR2 (0.69) MAPTALDH1A1LMNAKMT2ACNR2
SCHEMBL2162148 0.79 KMT2A (0.40) MAPTALDH1A1LMNAKMT2ACNR2
SCHEMBL5460031 0.79 MAPT (0.56) MAPTALDH1A1LMNAKMT2ACNR2
SCHEMBL5453100 0.79 CNR2 (0.67) MAPTALDH1A1LMNAKMT2ACNR2
SCHEMBL5460238 0.79 CNR2 (0.64) MAPTALDH1A1LMNAKMT2ACNR2
SCHEMBL4080042 0.78 CNR2 (0.76) MAPTALDH1A1LMNAKMT2ACNR2
SCHEMBL4094543 0.78 CNR2 (0.66) MAPTALDH1A1LMNAKMT2ACNR2
SCHEMBL5450611 0.78 CNR2 (0.66) MAPTALDH1A1LMNAKMT2ACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 MAPT 2527/4885ALDH1A1 1504/4885LMNA 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.